Tiruchy's opioid crisis: Young users turn to injected Tapentadol amid health risks

In the first seven months of this year, Mahatma Gandhi Memorial Government Hospital in Tiruchy admitted more than thirty patients seeking treatment for opioid dependence. That number alone tells part of the story. In all of 2025, the hospital treated forty such patients. In 2024, sixty-eight. The trajectory is unmistakable, and it is accelerating among the young.

The drug driving much of this surge is Tapentadol, a synthetic opioid increasingly favored by users in their late teens and twenties. What distinguishes this crisis from earlier patterns is the method of administration. A growing number of these young people are not swallowing tablets. They are dissolving them and injecting the solution directly into their veins, sometimes as frequently as every four hours. The consequences are compounding in ways that extend far beyond the individual user.

Consider the case of a twenty-six-year-old man now in treatment at the hospital. He began using Tapentadol at seventeen. By his own accounting, he spends roughly seven hundred rupees daily on the drug alone, and another three hundred on cannabis and alcohol combined. His monthly income is sixteen thousand rupees. The mathematics are brutal. He borrows from his parents and coworkers to sustain the habit. Five or six users in his circle pool their money to buy tablets, then share the injection equipment. This is how the virus travels.

Between June and August, ten patients in the hospital's drug-use cohort tested positive for Hepatitis C. Doctors point directly to syringe-sharing as the mechanism. But the medical complications extend beyond infection. Repeated injections cause serious damage to blood vessels and surrounding tissue. Hospital staff have documented patients experiencing seizures and fainting episodes after admission. The body accumulates injury with each puncture.

The nodal officer at the hospital's de-addiction center notes that most patients are between seventeen and thirty years old. Many are using multiple substances simultaneously—Tapentadol combined with alcohol and cannabis. This polysubstance dependence complicates both the diagnosis and the treatment. The center offers assessment, detoxification, counseling, and in appropriate cases, opioid-replacement therapy. Those who complete the program and leave addiction behind are doing well, the officer says. But more young people need to come forward.

The private sector is seeing the same pattern. Dr. A. Nithya, a consultant at Mercy Hospital, recalls that opioid cases were rare three years ago—perhaps three patients annually. Now the hospital admits two to three opioid-dependent patients each month, most in their early twenties or younger than thirty. The outpatient consultations have risen as well. The demand for treatment is real and growing.

Families are bearing the weight. One parent described the shock of discovering their son's opioid use after initially believing he was only using cannabis and alcohol. They noticed anxiety, behavioral shifts, violence erupting at home. The entire family fell into depression. The son eventually sought help himself and was admitted to the hospital. His story is not unique in Tiruchy right now.

The parallel market supplying these drugs remains active and accessible. Between June first and August twelfth, police seized thirty-four thousand Tapentadol tablets worth approximately eleven lakh rupees. More than one hundred people were arrested in operations targeting drug hotspots across the city. Officers say they are monitoring these locations closely, but the seizures themselves are evidence that the supply chain persists. Twenty-five or more private de-addiction centers are now operating in the district, a measure of how widespread the problem has become. The question now is whether treatment capacity can keep pace with demand, and whether families and communities can recognize the warning signs early enough to intervene.